ADRB2 Arg16Gly is associated with nocturnal asthma symptoms despite LABA use in two European pediatric asthma studies
S. Vijverberg (Amsterdam, Netherlands), T. Nguyen (Amsterdam, Netherlands), J. Perez-Garcia (San Cristobal de La Laguna, Spain), S. Hashimoto (Amsterdam, Netherlands), A. Neerincx (Amsterdam, Netherlands), M. Abdel-Aziz (Amsterdam, Netherlands), C. Almqvist (Stockholm, Sweden), O. Sardon Prado (San Sebastian, Spain), P. Corcuera (San Sebastian, Spain), J. Korta (San Sebastian, Spain), U. Potocnik (Maribor, Slovenia), M. Kabesch (Regensburg, Germany), A. Kraneveld (Utrecht, Netherlands), M. Pino-Yanes (San Cristobal de La Laguna, Spain), A. Maitland Van Der Zee (Amsterdam, Netherlands)
Source: International Congress 2022 – New insights into paediatric asthma diagnosis and management of severe asthma
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Vijverberg (Amsterdam, Netherlands), T. Nguyen (Amsterdam, Netherlands), J. Perez-Garcia (San Cristobal de La Laguna, Spain), S. Hashimoto (Amsterdam, Netherlands), A. Neerincx (Amsterdam, Netherlands), M. Abdel-Aziz (Amsterdam, Netherlands), C. Almqvist (Stockholm, Sweden), O. Sardon Prado (San Sebastian, Spain), P. Corcuera (San Sebastian, Spain), J. Korta (San Sebastian, Spain), U. Potocnik (Maribor, Slovenia), M. Kabesch (Regensburg, Germany), A. Kraneveld (Utrecht, Netherlands), M. Pino-Yanes (San Cristobal de La Laguna, Spain), A. Maitland Van Der Zee (Amsterdam, Netherlands). ADRB2 Arg16Gly is associated with nocturnal asthma symptoms despite LABA use in two European pediatric asthma studies. 2949
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|